• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

Klebsiella pneumoniae Infections - Pipeline Review, H1 2020

report cover
  • 30 April 2020
  • Pharmaceuticals
  • 128 Pages
  • Report Code: 24LS-1820
  • Formate :   
Download FREE Report Sample Download PDF File

Klebsiella pneumoniae Infections Pipeline Review H1 -MARKET ADVISORY SERVICES

Klebsiella pneumoniae Infections - Pipeline Review, H1 2020

Summary

We latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2020, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

We Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 27 and 12 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Klebsiella pneumoniae Infections - Overview
Klebsiella pneumoniae Infections - Therapeutics Development
Klebsiella pneumoniae Infections - Therapeutics Assessment
Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development
Klebsiella pneumoniae Infections - Drug Profiles
Klebsiella pneumoniae Infections - Dormant Projects
Klebsiella pneumoniae Infections - Discontinued Products
Klebsiella pneumoniae Infections - Product Development Milestones
Appendix
List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Klebsiella pneumoniae Infections - Pipeline by ABAC Therapeutics SA, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Acies Bio doo, H1 2020

Klebsiella pneumoniae Infections - Pipeline by AEON Medix Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Affinivax Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by BB200 LLC, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Bugworks Research India Pvt Ltd, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Celdara Medical LLC, H1 2020

Klebsiella pneumoniae Infections - Pipeline by ContraFect Corp, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Eligochem Ltd, H1 2020

Klebsiella pneumoniae Infections - Pipeline by EnBiotix Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Fedora Pharmaceuticals Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Forge Therapeutics Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Microbiotix Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Neoculi Pty Ltd, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Oryn Therapeutics, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, H1 2020

Klebsiella pneumoniae Infections - Pipeline by ReAlta Life Sciences Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by RemAb Therapeutics SL, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Soligenix Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Spero Therapeutics Inc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Summit Therapeutics Plc, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H1 2020

Klebsiella pneumoniae Infections - Pipeline by VaxNewMO LLC, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Vaxxilon AG, H1 2020

Klebsiella pneumoniae Infections - Pipeline by Venus Medicine Research Center, H1 2020

Klebsiella pneumoniae Infections - Dormant Projects, H1 2020

Klebsiella pneumoniae Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020

Klebsiella pneumoniae Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020

Klebsiella pneumoniae Infections - Discontinued Products, H1 2020List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020
ABAC Therapeutics SA

Acies Bio doo

AEON Medix Inc

Affinivax Inc

Akthelia Pharmaceuticals Ltd

Appili Therapeutics Inc

Armata Pharmaceuticals Inc

BB200 LLC

Bugworks Research India Pvt Ltd

Celdara Medical LLC

ContraFect Corp

Debiopharm International SA

Eligochem Ltd

EnBiotix Inc

F. Hoffmann-La Roche Ltd

Fedora Pharmaceuticals Inc

Forge Therapeutics Inc

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Microbiotix Inc

Neoculi Pty Ltd

Nosopharm SAS

Oryn Therapeutics

Peptilogics Inc

Phico Therapeutics Ltd

ReAlta Life Sciences Inc

RemAb Therapeutics SL

Shionogi & Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Summit Therapeutics Plc

Syntiron LLC

VaxNewMO LLC

Vaxxilon AG

Venus Medicine Research Center

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $1500

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase